Search
Obecabtagene autoleucel
go.drugbank.com/drugs/DB17362ApprovedInvestigationalObecabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy with a fast off-rate binding profile for CD19. … [A265040,A265045] It works by targeting B-cell-specific CD19 surface markers present on malignant B cells.
Synonyms: AUTOLOGOUS CD4+ AND CD8+ T CELLS, ENRICHED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) OBTAINED BY APHERESIS TRANSDUCED EX VIVO WITH A NON-REPLICATING, SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING, A CHIMERIC ANTIGEN RECEPTOR (CAR) CONSISTING OHydroxychloroquine
go.drugbank.com/drugs/DB01611ApprovedInvestigational[L14312]** Hydroxychloroquine was granted FDA approval on 18 April 1955.[L8072] A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.[A192546] … Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer.[A183047] Hydroxychloroquine is an aminoquinoline like [chloroquine].
Synonyms: 7-chloro-4-[5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline, 7-chloro-4-(4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinolineCobimetinib
go.drugbank.com/drugs/DB05239ApprovedInvestigationalIt has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. … Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction
Categories: UGT2B7 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexInosine
go.drugbank.com/drugs/DB04335ApprovedA purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose. … (Dorland, 28th ed)
Volanesorsen
go.drugbank.com/drugs/DB15067Approved[L16621] Volanesorsen was granted a conditional approval by the European Medicines Agency.[L16621] … [L16621] This drug is not commonly prescribed as it is used as an adjunct to diet in patients at high risk for pancreatitis, who have had inadequate response to triglyceride lowering therapy.
Products: NaSpectinomycin
go.drugbank.com/drugs/DB00919ApprovedVet approvedWithdrawnAn antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.
Medrogestone
go.drugbank.com/drugs/DB09124ApprovedWithdrawnMedrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone. … It was conceived as an alternative for an orally effective contraceptive option.[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing.
Mixtures: PRESOMEN 28 COMP 0.3/5MG, PRESOMEN 28 COMP 0.3/5MGCrizanlizumab
go.drugbank.com/drugs/DB15271ApprovedInvestigational[L10097] Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India. … Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease.
Nabilone
go.drugbank.com/drugs/DB00486ApprovedInvestigationalIf not provided in their activated form (such as through synthetic forms like Nabilone or [DB00470]), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A … From a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions.
Lonafarnib
go.drugbank.com/drugs/DB06448ApprovedInvestigationalaberrant farnesylated form of lamin A called progerin in the inner nuclear membrane. … Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature